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Background: The XRCC1 polymorphisms have been implicated in bladder cancer risk, but individually published
studies show inconsistent results. The aim of our study was to clarify the effects of XRCC1 variants on bladder
cancer risk.
Methods: A systematic literature search up to September 13, 2012 was carried out in PubMed, EMBASE and
Wanfang databases, and the references of retrieved articles were screened. Crude odds ratios with 95% confidence
intervals were used to assess the associations between XRCC1 Arg194Trp and Arg399Gln polymorphisms and
bladder cancer risk. Heterogeneity and publication bias were also evaluated.
Results: A total of 14 and 18 studies were eligible for meta-analyses of Arg194Trp and Arg399Gln, respectively.
Regrouping was adopted in accordance with the most probable appropriate genetic models. No obvious
heterogeneity between studies was found. For overall bladder cancer, the pooled odds ratios for Arg194Trp and
Arg399Gln were 1.69 (95% confidence interval: 1.25 to 2.28; P = 0.001) and 1.10 (95% confidence interval: 1.03 to
1.19; P = 0.008), respectively. After excluding the studies that were not in Hardy–Weinberg equilibrium, the
estimated pooled odds ratio still did not change at all.
Conclusions: The meta-analysis results suggest that XRCC1 Arg194Trp and Arg399Gln polymorphisms may be
associated with elevated bladder cancer risk.
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Bladder cancer is an important health problem worldwide.
It is the seventh most common malignancy in men and
seventeenth in women [1]. An estimated 386,300 new
cases and 150,200 deaths from bladder cancer occurred in
2008 worldwide [2]. However, the mechanism of bladder
cancer is not completely clear and is considered to be a
multifactorial process. The most established risk factors
for bladder cancer include cigarette smoking, occupational
exposure to arylamines and schistosomal infection [1].
These exogenous mutagens or carcinogens produce a
wide range of DNA lesions, bulky DNA adducts, and
DNA strand breaks. Epidemiologic evidence has shown* Correspondence: xielp@zjuem.zju.edu.cn
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reproduction in any medium, provided the orthat genetic variants at one or more loci result in reduced
DNA repair capacity and an increased cancer risk [3-5].
DNA carrying essential heritable information must
remain stable in order to undertake its key physiologic
functions, but it is continually vulnerable to many types of
endogenous and/or exogenous damage; thus, genetic
alterations could accumulate and tumorigenesis may
occur because of the damaged DNA. The DNA repair
system plays a pivotal role in maintaining the genome
integrity and stability through the reversal of DNA dam-
age. If accumulated genetic alterations occurred in corre-
sponding DNA repair genes, their reversal capacity could
be damaged, possibly increasing the risk of cancer in
carriers [6]. A large number of SNPs in common DNA
repair genes have been identified [7] and confirmed to be
associated with several sporadic cancers [8,9].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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located on chromosome 19q13.2–13.3, with 33 kb in
length, is an important component of base excision repair
(BER) [10]. BER consists of a series of consecutive steps
from the recognition and excision of a damaged base to
the ligation of broken points, which are mainly conducted
by XRCC1. When damage occurs, XRCC1 recruited by
DNA glycosylases, acts as a platform by regulating and
coordinating a whole list of BER proteins and single strand
break repair (SSBR) machinery [11,12]. Although there are
more than 300 validated SNPs in the XRCC1 gene
reported in the dbSNP database (http://www.ncbi.nlm.nih.
gov/SNP), two genetic changes including Arg194Trp on
exon 6 (rs1799782 in dbSNP, C/T) and Arg399Gln on
exon 10 (rs25487 in dbSNP, G/A) are the most extensively
studied. Many previous studies have been conducted to
evaluate the associations of XRCC1 polymorphisms with
bladder cancer risk. However, the results of these studies
remain inconsistent and contradictory, partially because a
single study may be too underpowered to detect a
possible small effect of the polymorphism on bladder
cancer, especially when the sample size is relatively
small. Thus, to clarify the effect of XRCC1 variants
(Arg194Trp and Arg399Gln) on bladder cancer risk,
we performed a meta-analysis of all eligible studies.Methods
Publication search
We carried out a systematic literature search in EMBASE,
PubMed and Wanfang databases, covering all the papers
published from their inception to September 13, 2012,
using the following key words: (XRCC1 or X-ray repair
cross-complementation group 1) and (bladder cancer or
bladder neoplasm or bladder tumor or urothelial cancer or
urinary tract cancer) and (polymorphism or variation or
variant or mutation or genotype or gene). There was no
language restriction. We evaluated potentially relevant
papers by checking their titles and abstracts and all the
studies matching the eligible criteria were retrieved.
Additional studies were identified by a manual search of
the references from retrieved articles and reviews.Inclusion criteria
Studies included in the present meta-analysis had to
meet all the following criteria: (a) evaluation of the
XRCC1 Arg194Trp and Arg399Gln polymorphisms and
the risk of bladder cancer, (b) had a case–control de-
sign or nested case–control design, (c) had sufficient
data for calculating an odds ratio (OR) with 95%
confidence interval (CI). If multiple publications from
the same population were available, the most recent
or largest study was eligible for inclusion in this
meta-analysis.Data extraction
Data were extracted independently by two authors using a
predefined data collection form, with disagreements being
resolved by consensus. For each study, the following infor-
mation was collected: first author’s last name, publication
year, the country in which the study was carried out,
ethnicity, numbers of cases and controls, genotyping
methods, genotypes, and allele frequency information.Quality assessment
The quality of each study was independently appraised by
the same two authors using the quality assessment criteria,
which were modified on the basis of previously published
meta-analysis of molecular association studies [13,14]. The
criteria consist of seven parameters of quality: repre-
sentativeness of the cases, representativeness of the con-
trols, ascertainment of bladder cancers, control selection,
genotyping examination, Hardy–Weinberg equilibrium
HWE) and total sample size. (The criteria are described in
detail in Additional file 1: Table S1). Scores ranged from 0
(worst) to 15 (best). Studies scoring <9 were classified as
low quality, and those ≥9 as high quality. Disagreements
were resolved by a joint reevaluation of the original article
with a third investigator.Statistical methods
HWE in cases and controls was examined again in our
meta-analysis using the goodness-of-fit test (significant
at the 0.05 level). The ORs and their 95% CIs were used to
calculate and assess the strength of the association
between XRCC1 Arg194Trp and Arg399Gln polymor-
phism and the risk of bladder cancer. If there was a statis-
tical heterogeneity among studies, the combined ORs and
95% CIs were estimated by the DerSimonian and Laird
method [15] in a random-effect model. Otherwise, the
ORs were obtained by the Mantel–Haenszel method [16]
in a fixed effect model.
ORs 1, 2, and 3 (OR1, OR2, and OR3) were calculated
for the genotypes: 1) TT versus CC, 2) CT versus CC, and
3) TT versus CT for Arg194Trp; and 1) AA versus GG, 2)
GA versus GG, and 3) AA versus GA for Arg399Gln,
respectively. These pairwise differences were used to
determine the most appropriate genetic model. If
OR1 = OR3 ≠1 and OR2 = 1, a recessive model is
implied. If OR1 = OR2 ≠ 1 and OR3 = 1, a dominant
model is suggested. If OR2 =1/OR3 ≠ 1 and OR1 = 1, then
a complete overdominant model is indicated. If OR1 >
OR2 >1 and OR1 > OR3 >1, or if OR1 < OR2 <1 and OR1
< OR3 < , then a codominant model is suggested.
Homogeneity of ORs across studies was tested by a
Chi-square-based Q statistic and the I2 score. Heterogeneity
was considered significant if the P-value was <0.10. The
value of I2 was used to assess the degree of heterogeneity
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heterogeneity; I2 >50% large or extreme heterogeneity).
Sensitivity analysis was performed in which the meta-
analysis estimates were computed after omission of every
study in turn. Cumulative meta-analyses of associations
for each SNP were also conducted through assortment of
studies with publication time.Evaluation of publication bias
Publication bias was assessed using Begg’s test (rank
correlation method) [17] and Egger’s test (linear
regression method) [18]. P <0.05 was considered to
be representative of a significant statistical publication
bias. All of the statistical analyses were performed
with STATA 11.0 (StataCorp, College Station, TX),
using two-sided P-values.Results
Characteristics of all included studies
Twenty studies were included in this meta-analysis on the
associations of the XRCC1 genetic polymorphisms with the
risk of bladder cancer. Of the selected studies, 14 [19-32]
were preliminarily appropriate for meta-analysis of
the associations with bladder cancer regarding
Arg194Trp, and 18 [19-22,24-28,30-38] were relevant
to the association with Arg399Gln. Tables 1 and 2
present the basic characteristics of each study
included in our meta-analysis and the corresponding
genotype distributions among cases and controls. TheTable 1 Main characteristics of the studies included in an ana
cancer risk
Study Ethnicity Country Sample size (Frequ
Case no
Stern [19] Caucasian US 235 (5.63)
Wu [20] Asian China 155 (33.87)
Matullo [21] Caucasian Mixed 131 (6.45)
Wu [22] Caucasian US 696 (6.43)
Zhang [23] Asian China 242 (33.47)
Sak [24] Caucasian UK 547 (5.79)
Figueroa [25] Caucasian Spain 1,150 (6.11)
Andrew [26] Caucasian US, Italy 1,029 (6.49)
Hsu [27] Asian Taiwan 221 (34.86)
Fontana [28] Caucasian France 51 (3.92)
Narter [29] Caucasian Turkey 83 (21.93)
Wang [30] Asian China 234 (31.62)
Bianchino [31] Caucasian Italy 32 (12.50)
Mittal [32] Asian India 212 (10.14)
HWE, Hardy–Weinberg equilibrium.literature search and study selection procedures are
shown in Figure 1.
Quantitative synthesis
For the Arg194Trp SNP, OR1, OR2, and OR3 were
1.835 (95%CI: 1.343 to 2.507), 1.026 (95%CI: 0.920
to 1.146), and 1.581 (95%CI: 1.154 to 2.165), respec-
tively, suggesting a recessive effect of the putative
susceptibility allele T. Thus, the original grouping
was collapsed, and CC and CT were combined, in
accordance with a recessive model, into a C carrier
group, the latter of which was compared with the
TT genotype group.
For the Arg399Gln SNP, OR1, OR2, and OR3 were
0.958 (95%CI: 0.850 to 1.080), 1.095 (95%CI: 1.014 to
1.183), and 0.884 (95%CI: 0.785 to 0.997), respectively, indi-
cating that a complete overdominant model was applicable,
that is, heterozygotes are at higher risk of bladder cancer
than either homozygotes (GG or AA).
As shown in Figures 2 and Table 3, the XRCC1
Arg194Trp polymorphism was associated with an increased
risk for bladder cancer in all subjects (OR = 1.69,
95% CI = 1.25 to 2.28, P = 0.001). Similarly, the
Arg399Gln polymorphism was also found to be signifi-
cantly associated with increased risk of bladder cancer
(OR = 1.10, 95% CI = 1.03 to 1.19, P = 0.008).
Evaluation of heterogeneity
For the Arg399Gln polymorphism, most I2 values of
heterogeneity were 0% and all P values were more thanlysis of the XRCC1 Arg194Trp polymorphism and bladder






213 (8.63) Yes 8 PCR-RFLP
155 (27.42) Yes 9 PCR-RFLP
1,094 (6.63) Yes 13 Taqman
629 (6.42) Yes 11 Taqman
225 (26.22) No 12 PCR-RFLP
579 (5.96) Yes 12 Taqman
1,149 (5.72) Yes 12 Taqman
1,281 (7.15) Yes 12 Taqman
223 (33.26) No 7 PCR-RFLP
45 (5.56) Yes 6 Taqman
45 (23.61) Yes 4 PCR-RFLP
253 (23.72) Yes 8 PCR-RFLP
242 (7.02) Yes 5 PCR-RFLP
250 (9.00) Yes 10 PCR-RFLP
Table 2 Main characteristics of the studies included in an analysis of the XRCC1 Arg399Gln polymorphism and bladder
cancer risk





methodCase no Control no
Stern [19] Caucasian US 235 (34.58) 213 (36.55) Yes 8 PCR-RFLP
Shen [33] Caucasian Italy 201 (32.09) 214 (34.11) Yes 9 PCR-RFLP
Sanyal [34] Caucasian Sweden 311 (35.21) 246 (31.71) Yes 9 PCR-RFLP
Broberg [35] Caucasian Sweden 61 (31.97) 155 (28.39) Yes 9 MALDI-TOF
Wu [20] Asian China 155 (27.74) 155 (46.45) Yes 8 PCR-RFLP
Matullo [21] Caucasian Mixed 131 (35.08) 1,094 (33.73) Yes 11 Taqman
Wu [22] Caucasian US 696 (34.01) 629 (33.72) Yes 10 Taqman
Karahalil [36] Caucasian Turkey 100 (32.00) 100 (38.00) Yes 7 PCR-RFLP
Sak [24] Caucasian UK 547 (35.71) 579 (36.52) Yes 11 Taqman
Figueroa [25] Caucasian Spain 1,150 (35.82) 1,149 (33.79) Yes 11 Taqman
Andrew [26] Caucasian US, Italy 1,029 (35.35) 1,281 (36.07) No 10 Taqman
Hsu [27] Asian Taiwan 221 (25.71) 223 (25.46) Yes 8 PCR-RFLP
Arizono [37] Asian Japan 251 (24.30) 251 (26.29) Yes 8 PCR-RFLP
Fontana [28] Caucasian France 51 (34.31) 45 (40.00) Yes 5 Taqman
Wang [30] Asian China 234 (32.26) 253 (29.45) Yes 7 PCR-RFLP
Bianchino [31] Caucasian Italy 32 (43.75) 242 (30.99) No 4 PCR-RFLP
Mittal [32] Asian India 212 (43.40) 250 (37.40) Yes 9 PCR-RFLP
Zhi [38] Asian China 302 (34.93) 311 (29.42) Yes 10 PCR-RFLP
HWE, Hardy–Weinberg equilibrium.
Figure 1 Flowchart of study assessment and selection.
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Figure 2 (See legend on next page.)
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Figure 2 Odds ratios (ORs) for associations between two single nucleotide polymorphisms (Arg194Trp and Arg399Gln) in the x-ray
repair cross-complementing group 1 gene (XRCC1) and bladder cancer risk. The size of the black square corresponding to each study is
proportional to the sample size and the center of each square represents the OR. The horizontal line shows the corresponding 95% CI of the OR.
Pooled OR is represented by a hollow diamond. A) Arg194Trp TT genotypes versus the CC-plus-CT genotype; B) Arg399Gln GA genotypes versus
the GG-plus-AA genotype. CI, confidence interval.
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between studies (Table 3). Similarly, for the Arg194Trp
polymorphism, there was also no obvious heterogeneity
between studies.Sensitivity analysis
In the sensitivity analysis, the influence of each study on
the pooled OR was examined by repeating the meta-
analysis while omitting each study, one at a time. This
procedure proved that our results were reliable and
robust. In addition, when excluding the studies that were
not in HWE, the estimated pooled OR still did not
change at all (data not shown).Cumulative meta-analysis
Cumulative meta-analyses of the two associations
were also conducted via the assortment of studies by
publication time. The 95% confidence intervals be-
came increasingly narrower with increasing sample
size, indicating that the precision of the estimates wasTable 3 Meta-analysis of the association between the XRCC1
the risk of bladder cancer
Polymorphism Stratification
factor
Sample size Number of
studiesCase Control O
Arg194Trp Overall 4,751 6,102 14 1.
Study in HWE 4,301 5,659 12 2.
Ethnicity
Asian 1,051 1,101 5 1.
Caucasian 3,700 5,001 9 1.
Study quality
High 3,956 5,111 8 2.
Low 795 991 6 1.
Arg399Gln Overall 5,654 7,136 18 1.
Study in HWE 4,632 5,641 16 1.
Ethnicity
Asian 1,364 1,438 6 1.
Caucasian 4,290 5,698 12 1.
Study quality
High 4,407 5,675 10 1.
Low 1,247 1,461 8 1.
CI, confidence interval; F, fixed-effect model; HWE, Hardy–Weinberg equilibrium; ORprogressively boosted by the continual addition of
more cases (data not shown).
Publication bias
There was no evidence of significant publication bias either
with the Begg’s test (Figures 3, P = 0.640 for
Arg194Trp; P = 0.820 for Arg399Gln) or with Egger’s
test (P = 0.345 for Arg194Trp; P = 0.248 for Arg399Gln).
Discussion
The Arg194Trp and Arg399Gln polymorphisms are
the most well characterized XRCC1 polymorphisms,
but the reported associations with bladder cancer
risk among studies are inconsistent. Our present
meta-analysis incorporating 20 case–control studies
suggests that the Arg194Trp and Arg399Gln poly-
morphisms are significantly associated with increased
bladder cancer risk.
In this meta-analysis, publication bias was not observed.
And there was no obvious heterogeneity between studies.
In addition, when repeating the meta-analysis by omittingArg194Trp and Arg399Gln genetic polymorphisms and
Test of association Test of heterogeneity
R (95% CI) P-value z Model I2 (%) P-value
69 (1.25-2.28) 0.001 3.39 F 35.9 0.112
07 (1.36-3.15) 0.001 3.38 F 0.0 0.575
97 (1.04-3.74) 0.038 2.08 R 64.1 0.025
44 (0.75-2.74) 0.270 1.10 F 0.0 0.538
08 (1.36-3.18) 0.001 3.36 F 0 0.458
35 (0.88-2.08) 0.352 0.93 R 71.6 0.030
10 (1.03-1.19) 0.008 2.67 F 0.0 0.596
08 (1.00-1.18) 0.053 1.94 F 0.0 0.858
14 (0.98-1.33) 0.082 1.74 F 0.0 0.562
09 (1.01-1.19) 0.037 2.09 F 0.0 0.460
10 (1.01-1.19) 0.028 2.20 F 0.0 0.819
13 (0.97-1.33) 0.122 1.55 R 28.1 0.204
, odds ratio; R, random-effect model.
Figure 3 Funnel plot of two single nucleotide polymorphisms (Arg194Trp and Arg399Gln) in the x-ray repair cross-complementing
group 1 gene (XRCC1) and bladder cancer risk. A) Arg194Trp; B) Arg399Gln.
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did not change at all. In view of these findings, we are
convinced that the results of our meta-analysis, in essence,
are sound and reliable.
The results of the present study are in contrast with a
previous meta-analysis published in 2008 [39], which
concluded that there was no association between the
XRCC1 polymorphisms and the risk for bladder cancer.
However, this study only included ten studies with
limited sample size (3,749 cases and 3,947 controls)
and, thus, it may lack sufficient statistical power to
detect the real association and may have generated a
fluctuated risk estimate.
Our findings have some biological plausibility. It is
widely accepted that certain genetic variants associated
with repair of DNA substantially increase the risk of
cancer in carriers because of the alteration of BER func-
tions [40]. BER is the primary DNA damage repair
pathway for the repairing of small base lesions resulting
from oxidation and alkylation damage [41]. As one of
the most important proteins in BER, XRCC1 is closely
related to BER pathway coordination by interacting with
most members of the BER short-patch pathway. SNP of
XRCC1 may increase the risk of some types of cancer by
damaging the interaction of XRCC1 with other enzym-
atic proteins and, consequently, altering DNA repair
activity [42]; this may result in carcinogenesis, including
a higher incidence of bladder cancer. Similar to the
results of our study, XRCC1 polymorphisms are also
reported to be associated with some other cancers. The
previous three meta-analyses have confirmed that the
Arg399Gln polymorphism is associated with risk of child-
hood acute lymphoblastic leukemia [43], breast cancer
[44], and prostate cancer among Asians [45]. Dai et al.
reported that the XRCC1 Arg194Trp polymorphism is
associated with an increased lung cancer risk [46] andthe study conducted by Li et al. suggested that the
Arg194Trp polymorphism may be associated with cer-
vical cancer risk [47]. By contrast, in our study, the
Arg194Trp polymorphism was associated with disease
risk only in Asians, but not in Caucasians. This is
mainly because the number of Caucasians is four-fold
higher than that of Asians and, therefore, the power
to detect association is higher.
Several limitations of this meta-analysis should be men-
tioned. First, the eligibility criteria for the inclusion of sub-
jects and sources of controls were different from each
other. No guarantee could be made among all those eligible
studies that there were no potential bladder cancer cases in
the controls. Second, because of the lack of the individual
original data, our results were just based on unadjusted es-
timates, and gene–gene and gene–environmental interac-
tions were not addressed in this meta-analysis. Third,
although the Begg’s test and Egger’s test did not reveal any
evidence of obvious publication bias, some inevitable publi-
cation bias may exist, because only studies published in
English and Chinese were included in our meta-analysis. Fi-
nally, as shown in Table 3, a borderline conclusion (OR:
1.08 (1.00 to 1.18)) of the Arg399Gln section was drawn
when two studies without HWE were excluded. This con-
clusion actually owed much to one study [26] with a rela-
tively large population weight, which implies the need for
more well-designed studies in future.
Conclusions
In conclusion, despite some limitations, the results of
our meta-analysis suggest that two polymorphisms in
XRCC1 (Arg194Trp and Arg399Gln) may contribute to
bladder cancer development. Whether it could be
applied to genotyping for clinical assessment requires
large-scale population studies among different ethnicities
and regions.
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